Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL62601 | 1.00 | DCPS (0.36) | DCPSADORA2APDPK1GDACASP1 | |
| Bromide SCHEMBL7862403 | 1.00 | DCPS (0.36) | DCPSADORA2APDPK1GDACASP1 | |
| SCHEMBL33841 | 0.96 | DCPS (0.38) | DCPSADORA2APDPK1GDACASP1 | |
| Hydrochloric Acid SCHEMBL19858969 | 0.92 | DCPS (0.36) | DCPSADORA2APDPK1GDACASP1 | |
| Hydrochloric Acid SCHEMBL63511 | 0.92 | DCPS (0.36) | DCPSADORA2APDPK1GDACASP1 | |
| Hydrochloric Acid SCHEMBL19858968 | 0.92 | DCPS (0.36) | DCPSADORA2APDPK1GDACASP1 | |
| Hydrochloric Acid SCHEMBL1450085 | 0.92 | DCPS (0.36) | DCPSADORA2APDPK1GDACASP1 | |
| SCHEMBL6944829 | 0.81 | PIK3CG (0.31) | DCPSADORA2APDPK1 | |
| SCHEMBL6943391 | 0.78 | CYP1A2 (0.31) | DCPSADORA2APDPK1CASP1 | |
| Sulfuric Acid SCHEMBL20815930 | 0.78 | PDPK1 (0.34) | DCPSADORA2APDPK1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867828-B2 | Aminopterin dosage forms | AMINOPTERIN LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1855682-B1 | AMINOPTERIN DOSAGE FORMS FOR INFLAMMATORY DISORDERS | AMINOPTERIN LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170128452-A1 | Aminopterin Dosage Forms | AMINOPTERIN LLC (US) | 2017-05-11 | — | — | US | disclosed |
| EP-1778237-B1 | Use of Aminopterin for treating acute lymphoblastic leukemia | AMINOPTERIN LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20120128703-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | KAMEN BARTON A (US) | 2012-05-24 | — | — | US | disclosed |
| US-8129383-B2 | Administering tablets containing less than 0.5 mg; uninterrupted dosage cycles; antiinflammatory agent; nontoxic; side effect reduction; antiarthritic agents; psoriasis, multiple, sclerosis, Crohn's disease, Lupus, Graft versus host disease | AMINOPTERIN LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100009998-A1 | Compositions and Methods Employing Aminopterin | KAMEN BARTON | 2010-01-14 | — | — | US | disclosed |
| US-7612071-B2 | Compositions and methods employing aminopterin | SYNTRIX BIOSYSTEMS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080108621-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | SYNTRIX BIOSYSTEMS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1855682-A4 | AMINOPTERIN DOSAGE FORMS AND METHODS FOR INFLAMMATORY DISORDERS | SYNTRIX BIOSYSTEMS INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20080096893-A1 | AMINOPTERIN DOSAGE FORMS | SYNTRIX BIOSYSTEMS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7312217-B2 | Aminopterin dosage forms and methods for inflammatory disorders | SYNTRIX BIOSYSTEMS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1855682-A2 | AMINOPTERIN DOSAGE FORMS AND METHODS FOR INFLAMMATORY DISORDERS | Syntrix Biosystems, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1778237-A1 | USE OF AMINOPTERIN FOR TREATING CANCER AND INFLAMMATORY DISORDERS | Syntrix Biosystems, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006098979-A2 | AMINOPTERIN DOSAGE FORMS AND METHODS FOR INFLAMMATORY DISORDERS | SYNTRIX BIOSYSTEMS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205729-A1 | Aminopterin dosage forms and methods for inflammatory disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-14 | — | — | US | disclosed |
| WO-2005089767-A1 | USE OF AMINOPTERIN FOR TREATING CANCER AND INFLAMMATORY DISORDERS | KAMEN BARTON ARON (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209239-A1 | Compositions and methods employing aminopterin | AMINOPTERIN LLC | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009998-A1 | Compositions and Methods Employing Aminopterin | SLC7A1, AADAT, SLC19A1 | DCPS 441/4885ADORA2A 964/4885PDPK1 4871/4885 |
| US-20080108621-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | AADAT, TPMT, RNPEP | DCPS 1038/4885ADORA2A 407/4885PDPK1 4839/4885 |
| US-20170128452-A1 | Aminopterin Dosage Forms | AADAT, TPMT, ANPEP | DCPS 3059/4885ADORA2A 212/4885PDPK1 4868/4885 |
| US-20120128703-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | AADAT, TPMT, RNPEP | DCPS 1038/4885ADORA2A 407/4885PDPK1 4839/4885 |
| US-20060205729-A1 | Aminopterin dosage forms and methods for inflammatory disorders | AADAT, ANPEP, TPMT | DCPS 2690/4885ADORA2A 275/4885PDPK1 4864/4885 |
| US-20080096893-A1 | AMINOPTERIN DOSAGE FORMS | AADAT, TPMT, ANPEP | DCPS 3059/4885ADORA2A 212/4885PDPK1 4868/4885 |
| US-20050209239-A1 | Compositions and methods employing aminopterin | SLC7A1, AADAT, SLC19A1 | DCPS 441/4885ADORA2A 964/4885PDPK1 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.